Form 4: Edgewise Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Kevin Koch, President and CEO and a Director of Edgewise Therapeutics, Inc., sold 17,971 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 17,969 Common Stock on August 12, 2026; holds 48,584 after (Direct).
- Option exercise/conversion: acquired 21,875 Common Stock on August 12, 2026; holds 70,459 after (Direct).
- Open-market sale: disposed of 8,782 Common Stock at $43.64 ($383,254) on August 12, 2026; holds 61,677 after (Direct).
- Open-market sale: disposed of 8,276 Common Stock at $43.66 ($361,315) on August 12, 2026; holds 53,401 after (Direct).
- Open-market sale: disposed of 913 Common Stock at $44.33 ($40,473) on August 12, 2026; holds 52,488 after (Direct).
- Option exercise/conversion: disposed of 17,969 Restricted Stock Units on August 12, 2026; holds 35,938 after (Direct).
- Option exercise/conversion: disposed of 21,875 Restricted Stock Units on August 12, 2026; holds 65,625 after (Direct).
- Grant/award: acquired 100,000 Restricted Stock Units on August 12, 2026; holds 100,000 after (Direct).
- Grant/award: acquired 200,000 Stock Option (Right to Buy) on August 12, 2026; holds 200,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $785,042 of stock on the open market.
Insider Transactions
Kevin Koch — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 17,969 | — | — | 48,584 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 21,875 | — | — | 70,459 |
| 2026-08-12 | Open-market sale | Common Stock | 8,782 | $44 | $383.3K | 61,677 |
| 2026-08-12 | Open-market sale | Common Stock | 8,276 | $44 | $361.3K | 53,401 |
| 2026-08-12 | Open-market sale | Common Stock | 913 | $44 | $40.5K | 52,488 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 17,969 | — | — | 35,938 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 21,875 | — | — | 65,625 |
| 2026-08-12 | Grant/award | Restricted Stock Units | 100,000 | — | — | 100,000 |
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 200,000 | — | — | 200,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (17,969 shares) |
| 2026-08-12 | Option exercise/conversion (21,875 shares) |
| 2026-08-12 | Open-market sale (8,782 shares) |
| 2026-08-12 | Open-market sale (8,276 shares) |
| 2026-08-12 | Open-market sale (913 shares) |
| 2026-08-12 | Option exercise/conversion (17,969 shares) |
| 2026-08-12 | Option exercise/conversion (21,875 shares) |
| 2026-08-12 | Grant/award (100,000 shares) |
| 2026-08-12 | Grant/award (200,000 shares) |
Keywords
insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., bearish, Kevin Koch
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.